Dr Theocharis Panaretakis graduated with a PhD in Experimental Oncology in 2003 from Karolinska Institutet, Sweden on molecular mechanisms of cell death induced by cornerstone anti-cancer drugs. He performed his postdoctoral studies at the Institut Gustave Roussy, France in Guido Kroemer’s lab on the immunogenicity of cell death and after that he returned to Karolinska institutet where in 2010 he set up his lab. He became Associate Professor or Experimental Oncology in 2010 and his main research interests involve mechanisms of action and resistance for clinically used anti-cancer agents against hematological malignancies (leukemia, myeloma) and solid tumors (breast and prostate cancer). He is currently a visiting faculty at MD Anderson Cancer Center, USA where he is continuing his main scientific interests on the molecular and functional properties of tumor microenvironment derived extracellular vesicles. In particular, Dr Panaretakis lab is looking for prognostic and predictive biomarkers that will inform the clinicians for patient stratification based on therapeutic benefit. These extracellular vesicle-enriched biomarkers also serve as the foundation for the identification of the cross talks between immune and non-immune components in the local and distant tumor microenvironment and thereby the identification of novel signaling cascades and therapeutic targets.
Abstracts this author is presenting: